NewsOur latest news and press releases. 2nd September 2026New telehealth service to help people diagnosed with AlkaptonuriaRead More 24th August 2026Cycle Pharmaceuticals launches CAVHANZA™ (nilotinib) Orally Disintegrating Tablets (ODT), designed for use with PPIs and H2RAs without food restrictions1Read More 2nd June 2026CAVHANZA™ (nilotinib) Orally Disintegrating Tablets: a new, FDA-approved treatmentRead More 3rd February 2026Cycle Pharmaceuticals Completes Acquisition of Applied TherapeuticsRead More 30th January 2026Cycle Pharmaceuticals Announces Additional Extension of Applied Therapeutics Tender OfferRead More 29th January 2026Cycle Pharmaceuticals Announces Further Extension of Applied Therapeutics Tender OfferRead More 28th January 2026Cycle Pharmaceuticals Announces Extension of Applied Therapeutics Tender OfferRead More 16th October 2025Cycle Pharmaceuticals launches its first oncology product, PHYRAGO™ (dasatinib) tablets, in the USRead More 21st July 2025Cycle Pharmaceuticals Signs Exclusive U.S. Sales License for PHYRAGO™ (dasatinib) TabletsRead More 17th July 2025Cycle Pharmaceuticals launches HARLIKU™ (nitisinone) Tablets, the first FDA-approved treatment for use in Alkaptonuria (AKU)Read More 19th June 2025Cycle Pharmaceuticals’ HARLIKU™ (nitisinone) Tablets Receive First FDA-Approval as Treatment for Alkaptonuria (AKU) Read More 22nd April 2025Cycle Pharmaceuticals launches Cycle Vita PKU™, an AI-powered smartphone app for on-the-go management of Phenylketonuria (PKU)Read More 31st March 2025Cycle Vita™ expands patient support in Multiple Sclerosis (MS) to include BAFIERTAM® (monomethyl fumarate) delayed-release capsulesRead More 18th March 2025New US product launch, VENXXIVA™ (tiopronin) Delayed-Release Tablets for the treatment of cystinuriaRead More 13th January 2025Cycle Pharma Acquires Banner Life Sciences, LLCRead More 5th November 2024Cycle Pharmaceuticals appoints Duncan Kennedy as Chief Financial OfficerRead More 14th October 2024Cycle Pharmaceuticals Reaffirms All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per ShareRead More 6th June 2024Cycle Pharmaceuticals Announces All-Cash Proposal to Acquire Vanda Pharmaceuticals for $8.00 Per ShareRead More 10th May 2024New US product, ORMALVI™ (dichlorphenamide) tablets launchesRead More 7th May 2024New tiopronin delayed-release tablets launch with patient support in the USRead More 15th January 2024Cycle Pharmaceuticals and Inceptua Group Partner for a Free Goods Programme for Patients with Hereditary Tyrosinemia Type 1 (HT-1) and Alkaptonuria (AKU)Read More 13th February 2023New drug, TASCENSO ODT® (fingolimod), launched to meet the needs of patients in the US left without essential patient supportRead More 16th January 2023Multiple sclerosis patients in US left without essential patient support program will now receive equivalent backing from Cycle Pharmaceuticals following FDA’s approval of TASCENSO ODT® (fingolimod)Read More 1st November 2022Cycle Pharmaceuticals to launch TASCENSO ODT® (fingolimod) in US in Q1 2023Read More 3rd October 2022New US product, JAVYGTOR™ (sapropterin dihydrochloride) Tablets and Powder, launches for Phenylketonuria (PKU) treatmentRead More 6th October 2021Tony Cates joins Cycle Group Holdings Board of DirectorsRead More 28th September 2021Cycle Pharmaceuticals launches SAJAZIR TM (icatibant) Injection, a new treatment option in Hereditary Angioedema (HAE)Read More 10th September 2021Cycle Pharmaceuticals Launches Cycle Vita™, a dedicated support platform for rare disease patientsRead More 15th March 2021NITYR (nitisinone) Tablets for Tyrosinaemia Type 1 receives Marketing Authorization in New ZealandRead More 14th September 2020US FDA Grants Once Daily Dosing Option For NITYR (nitisinone) Tablets for HT-1 PatientsRead More 8th September 2020Dr David Buckeridge Joins Cycle Group Holdings’ Board of DirectorsRead More 8th September 2020Cycle Pharmaceuticals Features in the Sunday Times Tech Track Ones to Watch 2020Read More 5th September 2020Cycle Pharmaceuticals Secures $25 Million Debt FinancingRead More 5th August 2020Cycle Launches COVID-19 Response For Eligible Patients with Tyrosinemia Type 1 (HT-1)Read More 13th May 2020Cycle Pharmaceuticals’ NITYR® (nitisinone) Tablets Receives Marketing Authorization in the Kingdom of Saudi ArabiaRead More 19th April 2020Cycle Pharmaceuticals Launches New Informative Online Meeting Series for Patients With Tyrosinemia Type 1 in the USRead More 13th March 2020Cycle Pharmaceuticals’ Supply Chain updateRead More 28th April 2019NITYR (nitisinone) Tablets for tyrosinaemia type 1 will be available with fully subsidised access on the Life Saving Drugs Program across AustraliaRead More 22nd November 2018Cycle Pharmaceuticals’ NITYR (nitisinone) tablets receives marketing authorization in ChileRead More 19th November 2018Longer shelf life for NITYR (nitisinone) tablets for HT-1 in the U.S. granted by the FDARead More 12th November 2018Cycle Pharmaceuticals Receives Approval for Updated Infant Administration for NITYR (nitisinone) Tablets for HT-1 in U.S.Read More 1st August 2017Cycle Pharmaceuticals Receives FDA Approval of Nityr™ (nitisinone) Tablets for Treatment of HT-1Read More 19th December 2016CYCLE Pharmaceuticals, The University of Cambridge and King’s College London Partner to Repurpose PARP Inhibitor Drugs for Vascular DiseaseRead More
